Vise Technologies Inc. Invests $5.56 Million in Gilead Sciences, Inc. $GILD

Vise Technologies Inc. bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 50,103 shares of the biopharmaceutical company’s stock, valued at approximately $5,555,000.

Other institutional investors have also modified their holdings of the company. Activest Wealth Management lifted its holdings in Gilead Sciences by 2,837.5% in the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 227 shares in the last quarter. GoalVest Advisory LLC boosted its stake in shares of Gilead Sciences by 7,566.7% during the 2nd quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Harbor Asset Planning Inc. acquired a new stake in shares of Gilead Sciences during the 2nd quarter valued at about $27,000. Putney Financial Group LLC lifted its stake in Gilead Sciences by 53.4% in the second quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after acquiring an additional 94 shares during the last quarter. Finally, Colonial Trust Advisors grew its position in Gilead Sciences by 304.3% in the first quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 213 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Gilead Sciences Stock Down 3.7%

Shares of NASDAQ:GILD opened at $118.84 on Monday. Gilead Sciences, Inc. has a 1 year low of $86.08 and a 1 year high of $124.61. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a market capitalization of $147.46 billion, a price-to-earnings ratio of 23.67, a P/E/G ratio of 0.81 and a beta of 0.32. The business’s 50-day moving average is $116.49 and its 200-day moving average is $112.26.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.31. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The business had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same period in the prior year, the firm posted $2.02 EPS. Gilead Sciences’s quarterly revenue was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities research analysts predict that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be paid a $0.79 dividend. The ex-dividend date is Monday, December 15th. This represents a $3.16 annualized dividend and a yield of 2.7%. Gilead Sciences’s dividend payout ratio (DPR) is currently 48.99%.

Wall Street Analyst Weigh In

Several equities analysts have commented on GILD shares. Morgan Stanley increased their price target on Gilead Sciences from $143.00 to $147.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Sanford C. Bernstein reiterated an “outperform” rating on shares of Gilead Sciences in a research note on Monday, November 3rd. Wells Fargo & Company lifted their price target on Gilead Sciences from $140.00 to $145.00 and gave the stock an “overweight” rating in a research report on Friday, October 31st. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $133.00 price objective on shares of Gilead Sciences in a research note on Friday, October 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $127.82.

Insider Activity at Gilead Sciences

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of the stock in a transaction on Wednesday, October 15th. The shares were sold at an average price of $118.08, for a total transaction of $354,240.00. Following the transaction, the insider directly owned 110,193 shares in the company, valued at approximately $13,011,589.44. This represents a 2.65% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 71,500 shares of company stock valued at $8,336,040. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.